Literature DB >> 26362956

Risk group characteristics and viral transmission clusters in South-East Asian patients infected with human immunodeficiency virus-1 (HIV-1) circulating recombinant form (CRF) 01_AE and subtype B.

Rebecca A Oyomopito1, Yen-Ju Chen2, Somnuek Sungkanuparph3, Rami Kantor4, Tuti Merati5, Wing-Cheong Yam6, Thira Sirisanthana7, Patrick C K Li6, Pacharee Kantipong8, Praphan Phanuphak9, Chris K C Lee10, Adeeba Kamarulzaman11, Rossana Ditangco12, Szu-Wei Huang2, Annette H Sohn13, Matthew Law1, Yi Ming A Chen14.   

Abstract

Human immunodeficiency virus (HIV)-1 epidemics in Asian countries are driven by varying exposures. The epidemiology of the regional pandemic has been changing with the spread of HIV-1 to lower-risk populations through sexual transmission. Common HIV-1 genotypes include subtype B and circulating recombinant form (CRF) 01_AE. Our objective was to use HIV-1 genotypic data to better quantify local epidemics. TASER-M is a multicenter prospective cohort of HIV-infected patients. Associations between HIV exposure, patient sex, country of sample origin and HIV-1 genotype were evaluated by multivariate logistic regression. Phylogenetic methods were used on genotypic data to investigate transmission relationships. A total of 1086 patients from Thailand, Hong Kong, Malaysia and the Philippines were included in analyses. Proportions of male patients within countries varied (Thailand: 55.6%, Hong Kong: 86.1%, Malaysia: 81.4%, Philippines: 93.8%; p < 0.001) as did HIV exposures (heterosexual contact: Thailand: 85.7%, Hong Kong, 46.2%, Malaysia: 47.8%, Philippines: 25.0%; p < 0.001). After adjustment, we found increased subtype B infection among men who have sex with men, relative to heterosexual-reported exposures (odds ratio = 2.4, p < 0.001). We further describe four transmission clusters of eight to 15 treatment naïve, predominantly symptomatic patients (two each for subtype B and CRF01_AE). Risk-group subpopulations differed with respect to the infecting HIV-1 genotype. Homosexual exposure patients had higher odds of being infected with subtype B. Where HIV-1 genotypes circulate within countries or patient risk-groups, local monitoring of genotype-specific transmissions may play a role in focusing public health prevention strategies. Phylogenetic evaluations provide complementary information for surveillance and monitoring of viruses with high mutation rates such as HIV-1 and Ebola.
Copyright © 2015. Published by Elsevier Taiwan.

Entities:  

Keywords:  Asia; CRF01_AE; HIV exposure; Subtype B

Mesh:

Year:  2015        PMID: 26362956      PMCID: PMC4929356          DOI: 10.1016/j.kjms.2015.07.002

Source DB:  PubMed          Journal:  Kaohsiung J Med Sci        ISSN: 1607-551X            Impact factor:   2.744


  11 in total

Review 1.  Evolutionary and immunological implications of contemporary HIV-1 variation.

Authors:  B Korber; B Gaschen; K Yusim; R Thakallapally; C Kesmir; V Detours
Journal:  Br Med Bull       Date:  2001       Impact factor: 4.291

2.  A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood.

Authors:  Stéphane Guindon; Olivier Gascuel
Journal:  Syst Biol       Date:  2003-10       Impact factor: 15.683

3.  Comparison of Bayesian and maximum-likelihood phylogenetic approaches in two legal cases involving accusations of transmission of HIV.

Authors:  Matthew Kaye; Doris Chibo; Chris Birch
Journal:  AIDS Res Hum Retroviruses       Date:  2009-08       Impact factor: 2.205

4.  MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods.

Authors:  Koichiro Tamura; Daniel Peterson; Nicholas Peterson; Glen Stecher; Masatoshi Nei; Sudhir Kumar
Journal:  Mol Biol Evol       Date:  2011-05-04       Impact factor: 16.240

5.  Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004.

Authors:  Joris Hemelaar; Eleanor Gouws; Peter D Ghys; Saladin Osmanov
Journal:  AIDS       Date:  2006-10-24       Impact factor: 4.177

6.  Reconstructing the epidemic history of HIV-1 circulating recombinant forms CRF07_BC and CRF08_BC in East Asia: the relevance of genetic diversity and phylodynamics for vaccine strategies.

Authors:  Yutaka Takebe; Huanan Liao; Saiki Hase; Rie Uenishi; Yue Li; Xiao-Jie Li; Xiaoxu Han; Hong Shang; Adeeba Kamarulzaman; Naoki Yamamoto; Oliver G Pybus; Kok Keng Tee
Journal:  Vaccine       Date:  2010-05-26       Impact factor: 3.641

7.  Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years--United States, 2008.

Authors:  Eileen Schneider; Suzanne Whitmore; Kathleen M Glynn; Kenneth Dominguez; Andrew Mitsch; Matthew T McKenna
Journal:  MMWR Recomm Rep       Date:  2008-12-05

8.  Continuous crossover(s) events of HIV-1 CRF01_AE and B subtype strains in Malaysia: evidence of rapid and extensive HIV-1 evolution in the region.

Authors:  Katherine A Lau; Bin Wang; Adeeba Kamarulzaman; Kee-Peng Ngb; Nitin K Saksena
Journal:  Curr HIV Res       Date:  2008-03       Impact factor: 1.581

9.  The LANL hemorrhagic fever virus database, a new platform for analyzing biothreat viruses.

Authors:  Carla Kuiken; Jim Thurmond; Mira Dimitrijevic; Hyejin Yoon
Journal:  Nucleic Acids Res       Date:  2011-11-07       Impact factor: 16.971

10.  Cohort profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) monitoring studies to evaluate resistance--HIV drug resistance in sub-Saharan Africa and the Asia-Pacific.

Authors:  Raph L Hamers; Rebecca Oyomopito; Cissy Kityo; Praphan Phanuphak; Margaret Siwale; Somnuek Sungkanuparph; Francesca Conradie; Nagalingeswaran Kumarasamy; Mariette E Botes; Thira Sirisanthana; Saade Abdallah; Patrick C K Li; Nicoletta Ngorima; Pacharee Kantipong; Akin Osibogun; Christopher K C Lee; Wendy S Stevens; Adeeba Kamarulzaman; Inge Derdelinckx; Yi-Ming Arthur Chen; Rob Schuurman; Michèle van Vugt; Tobias F Rinke de Wit
Journal:  Int J Epidemiol       Date:  2010-11-10       Impact factor: 7.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.